.Pharmacolibrary.Drugs.ATC.J.J04AK08 .Pharmacolibrary.Drugs.ATC.J.J04AK08| name: | Pretomanid |
| ATC code: | J04AK08 | route: | oral |
| n-compartments | 1 |
Pretomanid is a nitroimidazooxazine-class antibacterial drug used as part of combination therapy for the treatment of extensively drug-resistant, treatment-intolerant or non-responsive multidrug-resistant pulmonary tuberculosis in adults. It is approved by the US FDA (2019) and EMA as a component of specific multidrug regimens.
Pharmacokinetic parameters reported in healthy adult volunteers after oral administration, fasted or fed conditions, both sexes.
Lyons, MA (2018). Modeling and Simulation of Pretomanid Pharmacokinetics in Pulmonary Tuberculosis Patients. Antimicrobial agents and chemotherapy 62(7) –. DOI:10.1128/AAC.02359-17 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29661865
Zou, Y, et al., & Svensson, EM (2022). Characterizing Absorption Properties of Dispersible Pretomanid Tablets Using Population Pharmacokinetic Modelling. Clinical pharmacokinetics 61(11) 1585–1593. DOI:10.1007/s40262-022-01163-w PUBMED:https://pubmed.ncbi.nlm.nih.gov/36180816
Heinrich, N, et al., & Hoelscher, M (2025). Safety, bactericidal activity, and pharmacokinetics of the antituberculosis drug candidate BTZ-043 in South Africa (PanACEA-BTZ-043-02): an open-label, dose-expansion, randomised, controlled, phase 1b/2a trial. The Lancet. Microbe 6(2) 100952–None. DOI:10.1016/j.lanmic.2024.07.015 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39793592